Nuclear iASPP may facilitate prostate cancer progression

Cell Death and Disease

Volumn 5, Issue 10, 2014, Pages

  Morris, E V ^a,b   Cerundolo, L ^a,b   Lu, M ^a   Verrill, C ^c   Fritzsche, F ^a   White, M J ^a   Thalmann, G N ^d   Ten Donkelaar, C S ^a   Ratnayaka, I ^a   Salter, V ^a   Hamdy, F C ^b   Lu, X ^a   Bryant, R J ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d Department of Urology Inselspita ^*  (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INHIBITOR OF APOPTOSIS PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN OF P53; NUCLEAR PROTEIN; PROTEIN P53; PROTEIN P63; UNCLASSIFIED DRUG; PPP1R13L PROTEIN, HUMAN; PPP1R13L PROTEIN, MOUSE; REPRESSOR PROTEIN; SIGNAL PEPTIDE; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER MORTALITY; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; EPITHELIUM BASAL CELL; FOLLOW UP; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATE EPITHELIUM; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; ADULT; AGED; ANIMAL; CELL DIFFERENTIATION; COCULTURE; COHORT ANALYSIS; DISEASE COURSE; EPITHELIUM; HUMAN; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PHENOTYPE; PHOSPHORYLATION; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; TUMOR CELL LINE; TUMOR INVASION;

MUS; MUS MUSCULUS;

ADULT; AGED; ANIMALS; BIOMARKERS, TUMOR; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL NUCLEUS; COCULTURE TECHNIQUES; COHORT STUDIES; DISEASE PROGRESSION; EPITHELIUM; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; PHENOTYPE; PHOSPHORYLATION; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEINS;

EID: 84928010799     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.442     Document Type: Article

References (70)

1. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009; 9: 749-758.
2. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11-22.
3. Schlomm T, Iwers L, Kirstein P, Jessen B, Kollermann J, Minner S et al. Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol 2008; 21: 1371-1378.
4. Henke RP, Kruger E, Ayhan N, Hubner D, Hammerer P, Huland H. Immunohistochemical detection of p53 protein in human prostatic cancer. J Urol 1994; 152: 1297-1301.
5. Prendergast NJ, Atkins MR, Schatte EC, Paulson DF,Walther PJ. p53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma. J Urol 1996; 155: 1685-1692.
6. Voeller HJ, Sugars LY, Pretlow T, Gelmann EP. p53 oncogene mutations in human prostate cancer specimens. J Urol 1994; 151: 492-495.
7. Bostwick DG, Pacelli A, Lopez-Beltran A. Molecular biology of prostatic intraepithelial neoplasia. Prostate 1996; 29: 117-134.
8. Rinker-Schaeffer CW, Partin AW, Isaacs WB, Coffey DS, Isaacs JT. Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells. Prostate 1994; 25: 249-265.
9. Aprikian AG, Sarkis AS, Fair WR, Zhang ZF, Fuks Z, Cordon-Cardo C. Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J Urol 1994; 151: 1276-1280.
10. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 1993; 53: 3369-3373.
11. Eastham JA, Stapleton AM, Gousse AE, Timme TL, Yang G, Slawin KM et al. Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res 1995; 1: 1111-1118.
12. Effert PJ, McCoy RH, Walther PJ, Liu ET. p53 gene alterations in human prostate carcinoma. J Urol 1993; 150: 257-261.
13. Heidenberg HB, Sesterhenn IA, Gaddipati JP, Weghorst CM, Buzard GS, Moul JW et al. Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J Urol 1995; 154(2 Pt 1): 414-421.
14. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993; 85: 1657-1669.
15. Kubota Y, Shuin T, Uemura H, Fujinami K, Miyamoto H, Torigoe S et al. Tumor suppressor gene p53 mutations in human prostate cancer. Prostate 1995; 27: 18-24.
16. Muller PA, Trinidad AG, Timpson P, Morton JP, Zanivan S, van den Berghe PV et al. Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene 2013; 32: 1252-1265.
17. Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S et al. Mutant p53 drives invasion by promoting integrin recycling. Cell 2009; 139: 1327-1341.
18. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009; 137: 87-98.
19. Flores ER, Sengupta S, Miller JB, Newman JJ, Bronson R, Crowley D et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005; 7: 363-373.
20. Davis LD, Zhang W, Merseburger A, Young D, Xu L, Rhim JS et al. p63 expression profile in normal and malignant prostate epithelial cells. Anticancer Res 2002; 22: 3819-3825.
21. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000; 157: 1769-1775.
22. Pignon JC, Grisanzio C, Geng Y, Song J, Shivdasani RA, Signoretti S. p63-expressing cells are the stem cells of developing prostate, bladder, and colorectal epithelia. Proc Natl Acad Sci USA 2013; 110: 8105-8110.
23. Shah RB, Zhou M, LeBlanc M, Snyder M, Rubin MA. Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer. Am J Surg Pathol 2002; 26: 1161-1168.
24. Parsons JK, Gage WR, Nelson WG, De Marzo AM. p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology 2001; 58: 619-624.
25. Lu M, Breyssens H, Salter V, Zhong S, Hu Y, Baer C et al. Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP. Cancer Cell 2013; 23: 618-633.
26. Sullivan A, Lu X. ASPP: a new family of oncogenes and tumour suppressor genes. Br J Cancer 2007; 96: 196-200.
27. Trigiante G, Lu X. ASPP [corrected] and cancer. Nat Rev Cancer 2006; 6: 217-226.
28. Vives V, Su J, Zhong S, Ratnayaka I, Slee E, Goldin R et al. ASPP2 is a haploinsufficient tumor suppressor that cooperates with p53 to suppress tumor growth. Genes Dev 2006; 20: 1262-1267.
29. Kampa KM, Acoba JD, Chen D, Gay J, Lee H, Beemer K et al. Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damageresponse thresholds. Proc Natl Acad Sci USA 2009; 106: 4390-4395.
30. Tordella L, Koch S, Salter V, Pagotto A, Doondeea JB, Feller SM et al. ASPP2 suppresses squamous cell carcinoma via RelA/p65-mediated repression of p63. Proc Natl Acad Sci USA 2013; 110: 17969-17974.
31. Wang Y, Wang XD, Lapi E, Sullivan A, Jia W, He YW et al. Autophagic activity dictates the cellular response to oncogenic RAS. Proc Natl Acad Sci USA 2012; 109: 13325-13330.
32. Wang Y, Godin-Heymann N, Dan Wang X, Bergamaschi D, Llanos S, X Lu. ASPP1 and ASPP2 bind active RAS, potentiate RAS signalling and enhance p53 activity in cancer cells. Cell Death Differ 2013; 20: 525-534.
33. Wang XD, Lapi E, Sullivan A, Ratnayaka I, Goldin R, Hay R et al. SUMO-modified nuclear cyclin D1 bypasses Ras-induced senescence. Cell Death Differ 2011; 18: 304-314.
34. Sottocornola R, Royer C, Vives V, Tordella L, Zhong S, Wang Y et al. ASPP2 binds Par-3 and controls the polarity and proliferation of neural progenitors during CNS development. Dev Cell 2010; 19: 126-137.
35. Cong W, Hirose T, Harita Y, Yamashita A, Mizuno K, Hirano H et al. ASPP2 regulates epithelial cell polarity through the PAR complex. Curr Biol 2010; 20: 1408-1414.
36. Bergamaschi D, Samuels Y, O'Neil NJ, Trigiante G, Crook T, Hsieh JK et al. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet 2003; 33: 162-167.
37. Zhang X, Wang M, Zhou C, Chen S, Wang J. The expression of iASPP in acute leukemias. Leuk Res 2005; 29: 179-183.
38. Chen J, Xie F, Zhang L, Jiang WG. iASPP is over-expressed in human non-small cell lung cancer and regulates the proliferation of lung cancer cells through a p53 associated pathway. BMC Cancer 2010; 10: 694.
39. Liu Z, Zhang X, Huang D, Liu Y, Zhang X, Liu L et al. Elevated expression of iASPP in head and neck squamous cell carcinoma and its clinical significance. Med Oncol 2012; 29: 3381-3388.
40. Zhang B, Xiao HJ, Chen J, Tao X, Cai LH. Inhibitory member of the apoptosis-stimulating protein of p53 (ASPP) family promotes growth and tumorigenesis in human p53-deficient prostate cancer cells. Prostate Cancer Prostatic Dis 2011; 14: 219-224.
41. Notari M, Hu Y, Koch S, Lu M, Ratnayaka I, Zhong S et al. Inhibitor of apoptosis-stimulating protein of p53 (iASPP) prevents senescence and is required for epithelial stratification. Proc Natl Acad Sci USA 2011; 108: 16645-16650.
42. Chikh A, Matin RN, Senatore V, Hufbauer M, Lavery D, Raimondi C et al. iASPP/p63 autoregulatory feedback loop is required for the homeostasis of stratified epithelia. EMBO J 2011; 30: 4261-4273.
43. Slee EA, Gillotin S, Bergamaschi D, Royer C, Llanos S, Ali S et al. The N terminus of a novel isoform of human iASPP is required for its cytoplasmic localization. Oncogene 2004; 23: 9007-9016.
44. Taylor RA, Toivanen R, Risbridger GP. Stem cells in prostate cancer: treating the root of the problem. Endocr Relat Cancer 2010; 17: R273-R285.
45. Verhagen AP, Ramaekers FC, Aalders TW, Schaafsma HE, Debruyne FM, Schalken JA. Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Res 1992; 52: 6182-6187.
46. Bonkhoff H, Stein U, Remberger K. Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers. Hum Pathol 1994; 25: 42-46.
47. Hudson DL, Guy AT, Fry P, O'Hare MJ, Watt FM, Masters JR. Epithelial cell differentiation pathways in the human prostate: identification of intermediate phenotypes by keratin expression. J Histochem Cytochem 2001; 49: 271-278.
48. Xue Y, Smedts F, Debruyne FM, de la Rosette JJ, Schalken JA. Identification of intermediate cell types by keratin expression in the developing human prostate. Prostate 1998; 34: 292-301.
49. Isaacs WB, Carter BS, Ewing CM. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 1991; 51: 4716-4720.
50. Prtilo A, Leach FS, Markwalder R, Kappeler A, Burkhard FC, Cecchini MG et al. Tissue microarray analysis of hMSH2 expression predicts outcome in men with prostate cancer. J Urol 2005; 174: 1814-1818 discussion 1818.
51. Grisanzio C, Signoretti S. p63 in prostate biology and pathology. J Cell Biochem 2008; 103: 1354-1368.
52. Grisanzio C, Signoretti S. p63 in prostate biology and pathology. J Cell Biochem 2008; 103: 1354-1368. 52. Crum CP, McKeon FD. p63 in epithelial survival, germ cell surveillance, and neoplasia. Annu Rev Pathol 2010; 5: 349-371.
53. Signoretti S, Loda M. Defining cell lineages in the prostate epithelium. Cell Cycle 2006; 5: 138-141.
54. Weinstein MH, Signoretti S, Loda M. Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells. Mod Pathol 2002; 15: 1302-1308.
55. Shah RB, Kunju LP, Shen R, LeBlanc M, Zhou M, Rubin MA. Usefulness of basal cell cocktail (34betaE12+p63) in the diagnosis of atypical prostate glandular proliferations. Am J Clin Pathol 2004; 122: 517-523.
56. Wang Y, Hayward S, Cao M, Thayer K, Cunha G. Cell differentiation lineage in the prostate. Differentiation 2001; 68: 270-279.
57. van Leenders GJ, Gage WR, Hicks JL, van Balken B, Aalders TW, Schalken JA et al. Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Am J Pathol 2003; 162: 1529-1537.
58. Carroll DK, Carroll JS, Leong CO, Cheng F, Brown M, Mills AA et al. p63 regulates an adhesion programme and cell survival in epithelial cells. Nat Cell Biol 2006; 8: 551-561.
59. Chang CJ, Chao CH, Xia W, Yang JY, Xiong Y, Li CW et al. p53 regulates epithelialmesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 2011; 13: 317-323.
60. Cao L, Huang Q, He J, Lu J, Xiong Y. Elevated expression of iASPP correlates with poor prognosis and chemoresistance/radioresistance in FIGO Ib1-IIa squamous cell cervical cancer. Cell Tissue Res 2013; 352: 361-369.
61. Jiang L, Siu MK, Wong OG, Tam KF, Lu X, Lam EW et al. iASPP and chemoresistance in ovarian cancers: effects on paclitaxel-mediated mitotic catastrophe. Clin Cancer Res 2011; 17: 6924-6933.
62. Ananthanarayanan V, Deaton RJ, Yang XJ, Pins MR, Gann PH. Alpha-methylacyl-CoA racemase (AMACR) expression in normal prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): association with diagnosis of prostate cancer. Prostate 2005; 63: 341-346.
63. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 2003; 63: 1727-1730.
64. Hanson JA, Gillespie JW, Grover A, Tangrea MA, Chuaqui RF, Emmert-Buck MR et al. Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst 2006; 98: 255-261.
65. Mairinger T, Mikuz G, Gschwendtner A. Nuclear chromatin texture analysis of nonmalignant tissue can detect adjacent prostatic adenocarcinoma. Prostate 1999; 41: 12-19.
66. Mehrotra J, Varde S, Wang H, Chiu H, Vargo J, Gray K et al. Quantitative, spatial resolution of the epigenetic field effect in prostate cancer. Prostate 2008; 68: 152-160.
67. Nonn L, Ananthanarayanan V, Gann PH. Evidence for field cancerization of the prostate. Prostate 2009; 69: 1470-1479.
68. Tolonen TT, Tommola S, Jokinen S, Parviainen T, Martikainen PM. Bax and Bcl-2 are focally overexpressed in the normal epithelium of cancerous prostates. Scand J Urol Nephrol 2007; 41: 85-90.
69. Uetsuki H, Tsunemori H, Taoka R, Haba R, Ishikawa M, Kakehi Y. Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate. J Urol 2005; 174: 514-518.
70. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004; 22: 2790-2799.